logo-loader
RNS
Ananda Pharma Plc

Ananda Pharma PLC - Posting of Q&A

RNS Number : 9875I
Ananda Pharma PLC
26 November 2025
 

A logo with blue and green dots Description automatically generated

 26 November 2025

 

ANANDA PHARMA PLC

("Ananda" or the "Company")

Questions in relation to the Company's recent announcement about its proposed withdrawal from the AQSE Growth Market

 

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF),  a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, announced on 24 November that it will be seeking approval from its shareholders via a General Meeting to withdraw admission of the Company's ordinary shares of £0.002 each ("Ordinary Shares") from trading on the AQSE Growth Market pursuant to Rule 5.3 of the AQSE Growth Market Rulebook, together with proposals to re-register the Company as a private limited company, adopt new articles of association and change its name to Ananda Pharma Limited. Details of this announcement can be found here and details of the General Meeting can be found here.

The Company has received a number of questions from shareholders about the proposals to be considered at the General Meeting. Those questions and the answers from management can be found on the company's website here: https://investors.anandapharma.co.uk/activity-updates/PGNgYr-questions-in-relation-to-the-companys-recent-announcement-about-its-proposed-withdrawal-from-the-aqse-growth-market

Shareholders are encouraged to read the Company's circular in respect of the Delisting. The contents of this Q&A are intended to provide a high-level overview of questions asked by Shareholders since publication of the circular and not to be construed as legal, business or tax advice. Prospective investors should consult their own professional advisers for legal, financial or tax advice in relation to an investment or proposed investment in the Company. The contents of this Q&A must not be relied upon when making any investment or voting decision in respect of the Company's shares.

About Ananda Pharma

Ananda Pharma (AQSE: ANA) is a UK-based biopharmaceutical company developing regulatory approved, cannabidiol medicines to treat complex, chronic conditions, including endometriosis (funded by NHS Scotland) and chemotherapy pain (funded by NIHR).  The Company is led by successful entrepreneurs and is working with a team of world-class scientists, including globally respected Key Opinion Leaders at the University of Edinburgh.

 

For more information, please visit our website:

 

To stay up to date with Ananda's news please follow our social media channels:  

  

·              Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93

·              Instagram: https://www.instagram.com/anandapharmaplc/

·              LinkedIn:  https://www.linkedin.com/company/anandapharma

·              X: https://twitter.com/AnandaPlc

-Ends-

    

ANANDA PHARMA PLC 

+44 (0)7463 686 497 


ir@anandapharma.co.uk

 

Chief Executive Officer 


Melissa Sturgess 




Finance Director 


Jeremy Sturgess-Smith 


 


 

https://investors.anandapharma.co.uk/link/e9508e

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAUVSWRVOUAUAA
NO INVESTMENT ADVICE

This content is published by Proactive Investors Limited and made available subject to the terms and conditions of use of its website (see Terms of Use).

Proactive Investors is a full-service financial newswire. We produce independent, objective financial journalism and do not provide personalised investment advice, act as a broker, or recommend specific securities to individual investors.

Financial content published on this Site is produced under the journalist exemption provided for in Article 20 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, and in accordance with FCA guidance at PERG 8.12. Where a communication is not otherwise exempt, it is issued or approved for distribution in the UK by Proactive Investors Limited.

All information used in the preparation of this communication has been compiled from publicly available sources that we believe to be reliable, however, we cannot, and do not, guarantee the accuracy or completeness of this communication.

This communication is intended for information purposes only and does not constitute investment advice, a personal recommendation, an offer, solicitation, or inducement to buy or sell any investment or financial product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

This communication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider suitability for their individual circumstances and should read the relevant prospectus, term sheet, subscription agreement, information memorandum, prospectus or other offering document in full.

Past performance is not a reliable indicator of future results. The value of investments can fall as well as rise, and you may not recover the amount you invest.

This communication may contain information obtained from third parties, including credit ratings and financial data. Reproduction and distribution of third-party content in any form is prohibited except with the prior written consent of the relevant third party. Credit ratings are statements of opinion and should not be relied upon as investment advice.

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read